A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients with Advanced Solid Tumors

  • Gurney, Howard (Primary Chief Investigator)
  • Butala, Radhika, (Other)
  • Cunningham, Jacob, (Research Coordinator)

Project: OtherSponsored clinical trial

Description

Phase 1 study - solid tumours
Short titleHLX20-001
AcronymMISC_Covance Chiltern
StatusActive
Effective start/end date16/07/1815/07/23